A method for identifying, diagnosing, and monitoring cancerous
lung tissues in a subject may include measuring the expression of at least one biomarker in a biological sample in the subject, and comparing the expression against a normal value. When a
differential expression of the at least one biomarker between the biological sample and the normal value is more than 1.5-fold, the
lung tissue sample is cancerous. The at least one biomarker is selected from the group consisting of
peroxiredoxin I,
peroxiredoxin II,
peroxiredoxin III, peroxiredoxin IV, peroxiredoxin VI,
chaperonin,
amyloid-P-component,
annexin V, dihydropyrimidinase-like 2
protein, glutamate
carboxypeptidase, 2,3-bisphosphoglycerate
mutase,
thymidine phosphorylase, prolyl-4 hydroxylase,
selenium binding protein 1, β-mitochondrial
ATP synthase H+ transporting F1 complex,
laminin-
binding protein, minichromosome maintenance deficient
protein 5 variant,
keratin 9,
keratin 10, napsin A aspartic peptidase, M2-type
pyruvate kinase, and apolipoprotein A-I.